Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Revenue (2022 - 2025)

BioXcel Therapeutics has reported Revenue over the past 4 years, most recently at $256000.0 for Q4 2025.

  • Quarterly results put Revenue at $256000.0 for Q4 2025, down 30.05% from a year ago — trailing twelve months through Dec 2025 was $642000.0 (down 71.67% YoY), and the annual figure for FY2025 was $642000.0, down 71.67%.
  • Revenue for Q4 2025 was $256000.0 at BioXcel Therapeutics, up from $98000.0 in the prior quarter.
  • Over the last five years, Revenue for BTAI hit a ceiling of $1.1 million in Q2 2024 and a floor of -$1.6 million in Q2 2022.
  • Median Revenue over the past 4 years was $226000.0 (2022), compared with a mean of $191875.0.
  • Biggest five-year swings in Revenue: skyrocketed 3042.86% in 2023 and later tumbled 89.13% in 2025.
  • BioXcel Therapeutics' Revenue stood at $238000.0 in 2022, then soared by 57.98% to $376000.0 in 2023, then decreased by 2.66% to $366000.0 in 2024, then plummeted by 30.05% to $256000.0 in 2025.
  • The last three reported values for Revenue were $256000.0 (Q4 2025), $98000.0 (Q3 2025), and $120000.0 (Q2 2025) per Business Quant data.